@LT_Investor
What
@djwally is saying is correct
The user subscription fees you are referring to is when they start using the cloud, and that is later down the line with Beurer
The B Braun device they will receive license fees for and this should be sufficient to see them cashflow positive IMO
I think your last line is a bit rough though "Management are reluctant to buy in at this value. I done some research on them, there isnt much incentive for them to promote the company."
What research have you done on management that evidenced they are reluctant to buy or promote ?
I think you'll find given they are negotiating a fairly price sensitive weed MOU, that would generally exclude them from buying ... likewise being privvy to the B Braun launch date before the rest of the market
As for not promoting it, well let's see how the B Braun or weed MOU goes and judge from there
